



Article scientifique

Article

2020

Supplemental data

Open Access

This file is a(n) Supplemental data of:

Prospective long-term follow-up after first-line subcutaneous cladribine in
hairy cell leukemia: a SAKK trial

Benz, Rudolf; Arn, Kornelius; Andres, Martin; Pabst, Thomas; Baumann, Michael; Novak, Urban;
Hitz, Felicitas; Hess, Urs; Zenhausern, Reinhard; Chalandon, Yves; Mey, Ulrich; Blum, Sabine;
Rauch, Daniel; O'Meara Stern, Alix [and 10 more]

This publication URL:

<https://archive-ouverte.unige.ch/unige:143935>

Publication DOI:

[10.1182/bloodadvances.2020002160](https://doi.org/10.1182/bloodadvances.2020002160)

Supplemental files

Table: Early toxicity in different studies

First author	<i>Pooled Data SAKK</i>	von Rohr ¹⁵	Cheson ³⁵	Jehn ¹¹	Hoffman ³⁶	Grever ²⁹
Drug; iv/sc	Cld sc	Cld sc	Cld iv	Cld iv	Cld iv	2CDF iv
nausea/vomiting		only GI/II (no vomiting)	14/4/0.5/0.3	12/7/0/0		-/-/18/0
constipation/diarrhea		only G I/II	5/1/0/0.1	4/12/0/0		-/-/2/0
hemorrhage	46/5/0/1	-/-/-/1	2/2/0.6/0.6			
fever				14/20/0/2	GIII/IV 47%	-/-/2/0
infection	18/9/6/6	29/9/12 (GIII/IV)	1/13/13/3	5/5/0/0		
pneumonia			3/2//0.7/0.7			
skin reaction		only GI/II	8/5/4/0.5	7/7/0/0		-/-/4/0
neurologic (incl. headache)		1 GIII	18/6/1/0.1	12/9/0/0		-/-/1/0
other	80/12/6/3	1 GIII	15/8/7/2			
drug related death	0	0	10	0	0	3 early deaths

Early toxicity according to WHO grading as reported in several studies. (Cld: cladribine, 2CDF: pentostatin, sc.: subcutaneous, iv.: intravenous)